Novartis dispatches two more cancer drug castoffs to a partner in China
Novartis is sending two more of its oncology castoffs to a China biotech.
The pharma giant has out-licensed global rights to two of its cancer drugs — the AKT inhibitors afuresertib and uprosertib — to the Shanghai-based company Laekna. Novartis, in turn, picked them up in its big swap with GSK a few years ago, handing over vaccines in exchange for GSK’s late-stage cancer pipeline and products.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
